We report genome-wide effects of Ezh2 inhibition (GSK126) in MC3T3 sc4 pre-osteoblasts by ChIP-Seq (H3K27me3) and mRNA-Seq (transcriptome). Treatment of cells for 24 hours with GSK126 suppresses genome-wide H3K27me3, most notably near the transcriptional start sites (TSSs). Genes that exhibit suppression of H3K27me3 near TSSs as a result of GSK126 tend to be up-regulated at the mRNA levels (mRNA-Seq) as well. The mRNA-Seq analysis demonstrates that osteogenic genes are up-regulated after the administration of GSK126. These pro-osteogenic effects are seen 3, 6, and 10 days after the initial GSK126 treatment. SOURCE: Andre,J,van Wijnen (vanwijnen.andre@mayo.edu) -  Mayo Clinic

Pluto Bioinformatics

GSE83506: Ezh2 Inhibition is Bone-anabolic and Osteoprotective in Skeletally Mature Mice